Factor Xa inhibitors - Pipeline Insight, 2024

This “Factor Xa inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Factor Xa inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Factor Xa inhibitors Understanding

Factor Xa inhibitors: Overview

Inhibition of clotting factor Xa has been evaluated as a potential target for anticoagulation therapy with the hypothesis that using target-specific therapy will alleviate some of the dosing variability observed with the vitamin K antagonist. The FXa inhibitors have a unique mechanism of action compared with the VKA historically used for oral anticoagulation. FXa is common to both the intrinsic and extrinsic pathways of the clotting cascade making it an excellent target for anticoagulation therapy. It plays a significant role in the formation of thrombin from prothrombin. A single molecule of Xa leads to the creation of 1000 molecules of thrombin. Inhibition of Xa leads to a significant reduction in thrombin and ultimately clot formation
All of the currently available FXa inhibitors are contraindicated for use in patients experiencing active bleeding. In addition, they all carry United States (US) Black Boxed Warnings for premature discontinuation and spinal/epidural hematomas. The risk for ischemic events increases when FXa inhibitors are discontinued without an adequate alternative oral or parenteral anticoagulant in place. There is also a risk for the development of spinal/epidural hematomas when FXa inhibitors are used in patients undergoing spinal procedures including neuroaxial anesthesia and spinal puncture.

Currently available FXa inhibitors have been shown to be noninferior to warfarin with regards to efficacy and safety in clinical trials and are viable treatment options for patients with nonvalvular atrial fibrillation.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Factor Xa inhibitors R&D. The therapies under development are focused on novel approaches for Factor Xa inhibitors.

Factor Xa inhibitors Emerging Drugs Chapters

This segment of the Factor Xa inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Factor Xa inhibitors Emerging Drugs

Rivaroxaban: Bayer Rivaroxaban acts as inhibitor of Factor Xa. It is approved for Stroke, Embolism, VenousThromboembolism, Deep vein thrombosis. It is currently in phase III for Arterial thrombosis, Peripheral arterial disorders, Venous thrombosis and is being developed byBayer.

Factor Xa inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Factor Xa inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Factor Xa inhibitors

There are approx. 6+ key companies which are developing the Factor Xa inhibitors. The companies which have their Factor Xa inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Bayer.

Phases

This report covers around 6+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Factor Xa inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Factor Xa inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Factor Xa inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Factor Xa inhibitors drugs.

Factor Xa inhibitors Report Insights

• Factor Xa inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Factor Xa inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Factor Xa inhibitors drugs?
• How many Factor Xa inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Factor Xa inhibitors?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Factor Xa inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Factor Xa inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Chong Kun Dang Pharmaceutical
• Carbomimetics
• CSPC ZhongQi Pharmaceutical Technology
• Bayer
• AMAG Pharmaceuticals
• Pfizer

Key Products

• CKD-344
• CM20201
• SYHA-136
• Rivaroxaban
• Ciraparantag
• PF-05230907

This product will be delivered within 2 business days.